Functional Polymorphisms of FAS and FASL Gene and Risk of Breast Cancer - Pilot Study of 134 Cases

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Hashemi, Mohammad ^a,b   Fazaeli, Aliakbar ^b   Ghavami, Saeid ^c,d   Eskandari Nasab, Ebrahim ^b   Arbabi, Farshid ^b   Mashhadi, Mohammad Ali ^b   Taheri, Mohsen ^e   Chaabane, Wiem ^f,g   Jain, Mayur V ^f   Łos, Marek J ^f,h  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MANITOBA INSTITUTE OF CHILD HEALTH   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f LINKÖPING UNIVERSITY   (Sweden)

^g UNIVERSITY OF TUNIS   (Tunisia)

^h BioApplications Enterprises Winnipeg   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GENOMIC DNA;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FAS GENE; FASL GENE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; PILOT STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, CD95; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS;

TETRA;

EID: 84872256957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053075     Document Type: Article

References (59)

1. Stecklein SR, Jensen RA, Pal A, (2012) Genetic and epigenetic signatures of breast cancer subtypes. Frontiers in bioscience 4: 934-949.
2. Wiechec E, (2011) Implications of genomic instability in the diagnosis and treatment of breast cancer. Expert Rev Mol Diagn 11: 445-453.
3. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, et al. (2007) Breast cancer in Iran: an epidemiological review. Breast J 13: 383-391.
4. Babu GR, Samari G, Cohen SP, Mahapatra T, Wahbe RM, et al. (2011) Breast cancer screening among females in iran and recommendations for improved practice: a review. Asian Pacific journal of cancer prevention: APJCP 12: 1647-1655.
5. Gurevich-Panigrahi T, Panigrahi S, Wiechec E, Los M, (2009) Obesity: pathophysiology and clinical management. Curr Med Chem 16: 506-521.
6. Nordgard SH, Alnaes GI, Hihn B, Lingjaerde OC, Liestol K, et al. (2008) Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int J Cancer 123: 577-585.
7. Wiechec E, Hansen LL, (2009) The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol 625: 122-130.
8. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, et al. (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46: 497-510.
9. Wong RS, (2011) Apoptosis in cancer: from pathogenesis to treatment. Journal of experimental & clinical cancer research: CR 30: 87.
10. Evan GI, Vousden KH, (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348.
11. Fulda S, (2010) Modulation of apoptosis by natural products for cancer therapy. Planta medica 76: 1075-1079.
12. Los M, Wesselborg S, Schulze-Osthoff K, (1999) The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 10: 629-639.
13. Rashedi I, Panigrahi S, Ezzati P, Ghavami S, Los M, (2007) Autoimmunity and Apoptosis - Therapeutic Implications. Curr Med Chem 14: 3139-3159.
14. Los M, van de Craen M, Penning CL, Schenk H, Westendorp M, et al. (1995) Requirement of an ICE/Ced-3 protease for Fas/Apo-1-1mediated apoptosis. Nature 371: 81-83.
15. Villa-Morales M, Fernandez-Piqueras J, (2012) Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets.
16. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F, (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. The Journal of experimental medicine 184: 1075-1082.
17. Peduto Eberl L, Guillou L, Saraga E, Schroter M, French LE, et al. (1999) Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int J Cancer 81: 772-778.
18. O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F, et al. (2005) Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets 9: 1031-1044.
19. Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, et al. (2005) Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol 78: 359-371.
20. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M, (2001) Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 7: 2682-2692.
21. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, et al. (1997) Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90: 3118-3129.
22. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K, (1999) Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93: 3053-3063.
23. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, et al. (2001) Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97: 1378-1387.
24. Huang QR, Morris D, Manolios N, (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Molecular immunology 34: 577-582.
25. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, et al. (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63: 4327-4330.
26. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, et al. (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. International immunology 6: 1567-1574.
27. Wu J, Metz C, Xu X, Abe R, Gibson AW, et al. (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170: 132-138.
28. Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, et al. (2007) Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. Journal of pediatric hematology/oncology: official journal of the American Society of Pediatric Hematology/Oncology 29: 815-821.
29. Yang M, Sun T, Wang L, Yu D, Zhang X, et al. (2008) Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14: 3230-3236.
30. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, et al. (2010) Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res 9: 333-339.
31. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Taheri M, et al. (2010) The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 9: 1735-1741.
32. Hashemi M, Moazeni-Roodi A, Bahari A, Taheri M, (2012) A Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction for the Detection of rs8099917 IL28B Genotype. Nucleosides Nucleotides Nucleic Acids 31: 55-60.
33. Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, et al. (2000) Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 82: 1682-1688.
34. Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F, Mor G, (1999) The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast cancer research and treatment 54: 245-253.
35. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, et al. (2000) Prognostic relevance of altered Fas (CD95)-system in human breast cancer. International journal of cancer Journal international du cancer 89: 127-132.
36. Muschen M, Moers C, Warskulat U, Even J, Niederacher D, et al. (2000) CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 99: 69-77.
37. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, et al. (2000) FasL:Fas ratio-a prognostic factor in breast carcinomas. Cancer research 60: 822-828.
38. Martin TR, Hagimoto N, Nakamura M, Matute-Bello G, (2005) Apoptosis and epithelial injury in the lungs. Proceedings of the American Thoracic Society 2: 214-220.
39. Dufournet C, Uzan C, Fauvet R, Cortez A, Siffroi JP, et al. (2006) Expression of apoptosis-related proteins in peritoneal, ovarian and colorectal endometriosis. Journal of reproductive immunology 70: 151-162.
40. Ghavami S, Eshraghi M, Kadkhoda K, Mutawe MM, Maddika S, et al. (2009) Role of BNIP3 in TNF-induced cell death-TNF upregulates BNIP3 expression. Biochimica et biophysica acta 1793: 546-560.
41. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, et al. (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Laboratory investigation; a journal of technical methods and pathology 69: 415-429.
42. Bebenek M, Dus D, Kozlak J, (2007) Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Anticancer Res 27: 215-218.
43. Bebenek M, Dus D, Kozlak J, (2008) Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat. Adv Med Sci 53: 49-53.
44. Sun T, Miao X, Zhang X, Tan W, Xiong P, et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. Journal of the National Cancer Institute 96: 1030-1036.
45. Liu K, Caldwell SA, Abrams SI, (2005) Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer research 65: 4376-4388.
46. Zhang B, Sun T, Xue L, Han X, Lu N, et al. (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28: 1067-1073.
47. Sun T, Miao X, Zhang X, Tan W, Xiong P, et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1030-1036.
48. Sun T, Zhou Y, Li H, Han X, Shi Y, et al. (2005) FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202: 967-974.
49. Kurooka M, Nuovo GJ, Caligiuri MA, Nabel GJ, (2002) Cellular localization and function of Fas ligand (CD95L) in tumors. Cancer Res 62: 1261-1265.
50. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, et al. (2001) Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 32: 250-256.
51. Zhang X, Miao X, Sun T, Tan W, Qu S, et al. (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42: 479-484.
52. Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, et al. (2010) Polymorphisms in promoter region of FAS and FASL gene and risk of gastric cardiac adenocarcinoma. J Gastroenterol Hepatol 25: 555-561.
53. Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, et al. (2007) Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28: 2548-2551.
54. Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H, (2004) Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1478-1479; author reply 1479.
55. Zhang Z, Qiu L, Wang M, Tong N, Li J, (2009) The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 17: 1294-1303.
56. Wiechec E, Wiuf C, Overgaard J, Hansen LL, (2011) High-resolution melting analysis for mutation screening of RGSL1, RGS16, and RGS8 in breast cancer. Cancer Epidemiol Biomarkers Prev 20: 397-407.
57. Alavian SM, Ande SR, Coombs KM, Yeganeh B, Davoodpour P, et al. (2011) Virus-triggered autophagy in viral hepatitis- possible novel strategies for drug development. J Viral Hepat 18: 821-830.
58. Amaravadi RK, Thompson CB, (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13: 7271-7279.
59. Ghavami S, Mutawe MM, Sharma P, Yeganeh B, McNeill KD, et al. (2011) Mevalonate Cascade Regulation of Airway Mesenchymal Cell Autophagy and Apoptosis: A Dual Role for p53. PLoS One 6: e16523.